Summary
Platelets contribute significantly to arterial-occlusive thrombosis, one of the major causes of death and disease throughout the world. Consequently, inhibiting platelet function is a potentially important therapeutic goal. Among agents that inhibit platelet function, ticlopidine shows a wide spectrum of antiplatelet activity.
There have been a limited number of studies investigating the pharmacokinetic profile of the drug. However, it has been demonstrated that absorption of ticlopidine after oral administration is rapid, is improved when the drug is administered with food, but reduced by the coadministration of antacid. Ticlopidine is extensively metabolised, with little unchanged drug present in the plasma. After administration of a single dose, unchanged ticlopidine can be detected for up to 96 hours postdose. Repeated administration of ticlopidine 250mg twice daily results in 3- to 4-fold accumulation of the drug after 2 weeks. The terminal elimination half-life is between 20 and 50 hours.
Dosage selection is not determined by the pharmacokinetic profile of the drug, but rather by determination of the effect of the drug on bleeding time. The clearance of theophylline and Phenazone (antipyrine) are reduced by ticlopidine, resulting in increased plasma drug concentrations. In contrast, the plasma concentration of cyclosporin is reduced. Aspirin (acetylsalicylic acid) increases the bleeding time in patients receiving ticlopidine concurrently, while corticosteroids reduce bleeding time.
Ticlopidine use is discouraged in patients with severe organ failure. Furthermore, ticlopidine should be discontinued 2 weeks before surgery and dental intervention. Most importantly, the blood cell count should be monitored regularly during the 3 first months of treatment with ticlopidine because 1% of patients receiving ticlopidine may experience agranulocytosis.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Albers GW. Role of ticlopidine for prevention of stroke. Stroke 23: 912–916, 1992
Amoux P, Sales Y, Mandray M, et al. Quantitative high-performance liquid chromatographic, gas chromatographic-mass spectrometric analysis of ticlopidine in baboon plasma after solid-phase extraction. Journal of Pharmaceutical Sciences 80: 1092–1095, 1991
Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. Journal of Laboratory and Clinical Medicine 114: 84–91, 1989
Birmelé B, Lebranchu Y, Bagros Ph, et al. Interaction of cyclosporin and ticlopidine. Correspondence. Nephrology, Dialysis, Transplantation 6: 150–151, 1991
Bruno JJ, Molony BA. Ticlopidine. In Scriabine (Ed.). New drugs annual: cardiovascular drugs, pp. 295–316, Raven Press, New York, 1983
Colli A, Buccino G, Cocciolo M, et al. Ticlopidine-theophylline interaction. Clinical Pharmacology and Therapeutics 41: 358–362, 1987
Combalbert J, Savi P, Rouchon MC, et al. Influence of hepatic cytochrome P450 subfamilies induction on the antiaggregating activity and on the microsomal hepatic metabolism of the thienopyridine clopidogrel (SR 25990C). Abstract of proceedings of the Thirteenth European Workshop on Drug Metabolism, Bergamo, Italy, September 21–25, 1992
Dembinska-Kiec A, Virgolini I, Rauscha F, et al. Ticlopidine and platelet function in healthy volunteers. Thrombosis Research 65: 559–570, 1992
Desager JP, Van Nieuwenhuyze Y, Dricot J, et al. Pharmacokinetic profile and bioavailability of a new galenic formulation of ticlopidine. International Journal of Clinical Pharmacology Research 10: 247–250, 1990
Di Minno G, Cerbone A, Mattioli P, et al. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. Journal of Clinical Investigation 75: 328–338, 1985
Dukes MNG (Ed.). Meyler’s side effects of drugs, p. 908, Elsevier, Amsterdam, 1992
Fujimaki Y, Tsumura M, Tachizawa H. High performance liquid chromatographic method for the determination of ticlopidine in human serum. In Japanese. Journal of The Pharmaceutical Society of Japan (Yakugaku Zasshi) 106: 1143–1145, 1986
Gachet C, Cazenave JP, Ohlmann P, et al. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochemical Pharmacology 40: 2683–2687, 1990a
Gachet C, Stierle A, Cazenave JP, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein Ilb-IIIa complex in rat and in man. Biochemical Pharmacology 40: 229–238, 1990b
Godard P, Zini R, Metay A, et al. The fate of ticlopidine in the organism-I: distribution and elimination of ticlopidine 14C after a single intravenous injection in the rat. European Journal of Drug Metabolism and Pharmacokinetics 3: 67–71, 1978
Godard P, Zini R, Metay A, et al. The fate of ticlopidine in the organism-II: distribution and elimination of ticlopidine 14C after a single oral administration in the rat. European Journal of Drug Metabolism and Pharmacokinetics 4: 133–138, 1979
Gralnick H, Williams S, McKeown L, et al. Platelet von Willebrand Factor. Mayo Clinic Proceedings 66: 634–640, 1991
Haynes RB, Sandler RS, Larson EB, et al. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Archives of Internal Medicine 1152: 1376–1380, 1992
Herbert JM, Frehel D, Bernat A, et al. Clopidogrel hydrogenosulfate. Drugs of the Future 18: 107–112, 1993
Ito MK, Smith AR, Lee ML. Ticlopidine: a new platelet aggregation inhibitor. Clinical Pharmacy 11: 603–617, 1992
Itoh S, Suzuki S, Ando S, et al. Determination of ticlopidine in rabbit plasma by high-performance liquid chromatography. Chemical and Pharmaceutical Bulletin 35: 1304–1307, 1987
Knudsen JB, Bastain W, Sefton CM, et al. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 22: 579–589, 1992
Maffrand JP, Eloy F. Synthèse de thienopyridines et de furopyridines d’intérêt thérapeutique. European Journal of Medicinal Chemistry 9: 483–486, 1974
Mataix R, Ojeda E, Perez MC, et al. Ticlopidine and severe aplastic anemia (case report). British Journal of Haematology 80: 125–126, 1992
McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 40: 238–259, 1990
Meyer D, Pietu G, Fressinaud E, et al. Von Willebrand Factor: structure and function. Mayo Clinic Proceedings 66: 516–523, 1991
Mills DCB, Puri R, Hu C-J, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arteriosclerosis Thrombosis 12: 430–436, 1992
Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 337: 774–776, 1991
Panak E, Maffrand JP, Picard-Fraire C, et al. Ticlopidine a promise for the prevention and treatment of thrombosis and its complications. Haemostasis 13 (Suppl. 1): 1–54, 1983
Picard-Fraire C. Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function. Thrombosis Research (Suppl. 4): 119–128, 1983
Picard-Fraire C. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents and Actions 15 (Suppl.): 68–75, 1984
Qian S, Iwai T. Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease. Angiology 44: 627–631, 1993
Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 34: 222–262, 1987
Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochemical Pharmacology 44: 527–532, 1992
Shah J, Fratis A, Ellis D, et al. Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. Journal of Clinical Pharmacology 30: 733–736, 1990
Shah J, Teitelbaum P, Molony B, et al. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. British Journal of Clinical Pharmacology 32: 761–764, 1991
Smith SA, Ellis DJ, Reitman MA, et al. Metabolic fate of ticlopidine hydrochloride in humans. Abstract, FASEB J 2: A1063, 1988
Takegoshi T, Ono K, Matsubayashi K, et al. Metabolic disposition of ticlopidine hydrochloride, a new antithrombotic agent, in rats. In Japanese. Ouyou Yakuri 19: 349–361, 1980
Tuong A, Bouyssou A, Paret J, et al. Metabolism of ticlopidine in rats: identification and quantitative determination of some of its metabolites in plasma, urine and bile. European Journal of Drug Metabolism and Pharmacokinetics 6: 91–98, 1981
Verstraete M. Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases. Drugs 42 (Suppl. 5): 22–38, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Desager, JP. Clinical Pharmacokinetics of Ticlopidine. Clin. Pharmacokinet. 26, 347–355 (1994). https://doi.org/10.2165/00003088-199426050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199426050-00003